Escitalopram has emerged as one of the strongest antidepressant options for preventing relapse, after a large analysis found that three pill-based treatments performed better than Prozac in maintaining recovery among patients treated for depression. The finding places renewed attention on how doctors choose long-term therapy for people whose symptoms have improved but who remain at risk of returning episodes.
The analysis compared antidepressants for their ability to prevent relapse rather than only to reduce symptoms during an acute depressive phase. That distinction matters in clinical practice: many patients continue medication after improvement to reduce the likelihood that depression will recur. Escitalopram, a selective serotonin reuptake inhibitor, was identified among the leading treatments, while Prozac, the brand name for fluoxetine, was outperformed by the top-ranked pills.
The results add to a long-running debate about how best to balance effectiveness, tolerability and patient preference in the use of antidepressants. Medicines in the same broad class can differ in how patients respond to them, and relapse prevention is only one part of prescribing decisions. Side effects, previous treatment history, other medical conditions and the risk of withdrawal symptoms all remain relevant when clinicians review whether a patient should continue, change or stop treatment.
Depression is a major public health issue, with the World Health Organization describing it as a common mental disorder that can affect everyday functioning and quality of life. For health systems, relapse is particularly important because recurring episodes can increase the need for further medical appointments, psychological support and time away from work or study. Evidence that some medicines may be more effective at sustaining remission can therefore influence prescribing guidelines and shared decision-making.
The analysis does not mean that one antidepressant is the best choice for every patient, nor does it support abrupt medication changes without medical supervision. It does, however, strengthen the evidence base around escitalopram and other high-performing treatments in relapse prevention. For patients already taking Prozac or another antidepressant, the practical implications depend on individual response and clinical assessment, rather than rankings alone.